SBRT-SG-01 : final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases
© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO)..
OBJECTIVE: This study aimed to assess the efficacy and tolerability of stereotactic body radiation therapy (SBRT) for the treatment of liver metastases.
METHODS: Patients with up to 5 liver metastases were enrolled in this prospective multicenter study and underwent SBRT. Efficacy outcomes included in-field local control (LC), progression-free survival (PFS), and overall survival (OS). Acute and late toxicities were evaluated using CTCAE v.4.0.
RESULTS: A total of 52 patients with 105 liver metastases were treated between 2015 and 2018. The most common primary tumor was colorectal cancer (72% of cases). Liver metastases were synchronous with the primary tumor diagnosis in 24 patients (46.2%), and 21 patients (40.4%) presented with other extrahepatic oligometastases. All patients underwent intensity-modulated radiation therapy (IMRT)/volumetric-modulated arc therapy (VMAT) with image-guided radiation therapy (IGRT) and respiratory gating, and a minimum biologically effective dose (BED10Gy) of 100 Gy was delivered to all lesions. With a median follow-up of 23.1 months (range: 13.4-30.9 months) since liver SBRT, the median actuarial local progression-free survival (local-PFS) was not reached. The actuarial in-field LC rates were 84.9% and 78.4% at 24 and 48 months, respectively. The median actuarial liver-PFS and distant-PFS were 11 and 10.8 months, respectively. The actuarial median overall survival (OS) was 27.7 months from SBRT and 52.5 months from metastases diagnosis. Patients with lesion diameter ≤ 5 cm had significantly better median liver-PFS (p = 0.006) and OS (p = 0.018). No acute or late toxicities of grade ≥ 3 were observed.
CONCLUSIONS: This prospective multicenter study confirms that liver SBRT is an effective alternative for the treatment of liver metastases, demonstrating high rates of local control and survival while maintaining a low toxicity profile.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - (2024) vom: 02. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rodríguez, María-Carmen Rubio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 02.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s12094-024-03403-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369214161 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369214161 | ||
| 003 | DE-627 | ||
| 005 | 20240304233026.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12094-024-03403-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM369214161 | ||
| 035 | |a (NLM)38431539 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rodríguez, María-Carmen Rubio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SBRT-SG-01 |b final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO). | ||
| 520 | |a OBJECTIVE: This study aimed to assess the efficacy and tolerability of stereotactic body radiation therapy (SBRT) for the treatment of liver metastases | ||
| 520 | |a METHODS: Patients with up to 5 liver metastases were enrolled in this prospective multicenter study and underwent SBRT. Efficacy outcomes included in-field local control (LC), progression-free survival (PFS), and overall survival (OS). Acute and late toxicities were evaluated using CTCAE v.4.0 | ||
| 520 | |a RESULTS: A total of 52 patients with 105 liver metastases were treated between 2015 and 2018. The most common primary tumor was colorectal cancer (72% of cases). Liver metastases were synchronous with the primary tumor diagnosis in 24 patients (46.2%), and 21 patients (40.4%) presented with other extrahepatic oligometastases. All patients underwent intensity-modulated radiation therapy (IMRT)/volumetric-modulated arc therapy (VMAT) with image-guided radiation therapy (IGRT) and respiratory gating, and a minimum biologically effective dose (BED10Gy) of 100 Gy was delivered to all lesions. With a median follow-up of 23.1 months (range: 13.4-30.9 months) since liver SBRT, the median actuarial local progression-free survival (local-PFS) was not reached. The actuarial in-field LC rates were 84.9% and 78.4% at 24 and 48 months, respectively. The median actuarial liver-PFS and distant-PFS were 11 and 10.8 months, respectively. The actuarial median overall survival (OS) was 27.7 months from SBRT and 52.5 months from metastases diagnosis. Patients with lesion diameter ≤ 5 cm had significantly better median liver-PFS (p = 0.006) and OS (p = 0.018). No acute or late toxicities of grade ≥ 3 were observed | ||
| 520 | |a CONCLUSIONS: This prospective multicenter study confirms that liver SBRT is an effective alternative for the treatment of liver metastases, demonstrating high rates of local control and survival while maintaining a low toxicity profile | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Liver metastases | |
| 650 | 4 | |a Oligometastases | |
| 650 | 4 | |a SBRT | |
| 700 | 1 | |a Chen-Zhao, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Hernando, Ovidio |e verfasserin |4 aut | |
| 700 | 1 | |a Flamarique, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Letón, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Campo, Maider |e verfasserin |4 aut | |
| 700 | 1 | |a López, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, Maitane |e verfasserin |4 aut | |
| 700 | 1 | |a Zucca, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Saugar, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Mañeru, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Zorrilla, Juan García |e verfasserin |4 aut | |
| 700 | 1 | |a de Acilu, Paz García |e verfasserin |4 aut | |
| 700 | 1 | |a Valero, Jeannette |e verfasserin |4 aut | |
| 700 | 1 | |a Montero, Angel |e verfasserin |4 aut | |
| 700 | 1 | |a Ciérvide, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarez, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a García-Aranda, Mariola |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a de la Casa, Miguel Angel |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Leyre |e verfasserin |4 aut | |
| 700 | 1 | |a Nuñez, Mónica |e verfasserin |4 aut | |
| 700 | 1 | |a Martí, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Arias, Fernando |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico |d 2005 |g (2024) vom: 02. März |w (DE-627)NLM155341065 |x 1699-3055 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:02 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12094-024-03403-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 02 |c 03 | ||